208
Participants
Start Date
October 1, 2025
Primary Completion Date
July 31, 2028
Study Completion Date
October 31, 2028
Infliximab
"The TNF-α antagonist (infliximab) used by the experimenter was manufactured by Hisun Biopharmaceuticals Ltd. under the trade name anbaite.The dosage was administered at 5 mg/kg, dissolved in 250 mL of 0.9% sodium chloride injection, and delivered via intravenous infusion over 2 hours."
Sodium chloride injection USP, 0.9% (placebo)
Patients in the control group received 250 mL of 0.9% sodium chloride injection as a placebo, administered via intravenous infusion over 2 hours.
Peking University First Hospital
OTHER
Peking University People's Hospital
OTHER
Peking University Shenzhen Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
Jiangsu Provincial People's Hospital
OTHER
Hunan Provincial People's Hospital
OTHER
Sichuan Provincial People's Hospital
OTHER
People's Hospital of Guangxi Zhuang Autonomous Region
OTHER
People's Hospital of Xinjiang Uygur Autonomous Region
OTHER
Renmin Hospital of Wuhan University
OTHER
Peking University Third Hospital
OTHER